Groupama Asset Managment Buys New Shares in STERIS plc $STE

21 Mar 2026, 09:20 by Kim Johansen · The Markets Daily

Groupama Asset Managment bought a new position in shares of STERIS plc (NYSE:STE – Free Report) in the third quarter, Holdings Channel reports. The fund bought 4,701 shares of the medical equipment provider’s stock, valued at approximately $1,163,000.

Several other institutional investors also recently modified their holdings of STE. CIBC Bancorp USA Inc. bought a new stake in shares of STERIS during the 3rd quarter worth $3,361,000. Caerus Investment Advisors LLC acquired a new stake in shares of STERIS during the third quarter worth $531,000. Captrust Financial Advisors raised its position in shares of STERIS by 0.9% during the third quarter. Captrust Financial Advisors now owns 203,636 shares of the medical equipment provider’s stock worth $50,388,000 after purchasing an additional 1,851 shares during the period. Danske Bank A S purchased a new stake in shares of STERIS during the third quarter valued at $19,216,000. Finally, Advisory Services Network LLC acquired a new position in shares of STERIS in the 3rd quarter valued at $68,000. Institutional investors own 94.69% of the company’s stock.

Insider Activity

In other news, Director Cynthia L. Feldmann sold 3,098 shares of the business’s stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $237.21, for a total transaction of $734,876.58. Following the sale, the director directly owned 705 shares in the company, valued at approximately $167,233.05. The trade was a 81.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 1.07% of the company’s stock.

STERIS Stock Up 1.1%

Shares of STE opened at $220.24 on Friday. The company has a 50-day simple moving average of $246.98 and a 200-day simple moving average of $249.53. The firm has a market capitalization of $21.60 billion, a P/E ratio of 30.72 and a beta of 1.05. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.75 and a current ratio of 2.48. STERIS plc has a 52 week low of $204.90 and a 52 week high of $269.44.

STERIS (NYSE:STE – Get Free Report) last released its earnings results on Wednesday, February 4th. The medical equipment provider reported $2.53 earnings per share for the quarter, hitting analysts’ consensus estimates of $2.53. STERIS had a return on equity of 14.34% and a net margin of 12.15%.During the same quarter in the prior year, the firm earned $2.32 EPS. The company’s revenue for the quarter was up 9.2% compared to the same quarter last year. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. On average, equities research analysts expect that STERIS plc will post 9.08 earnings per share for the current year.

STERIS Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 19th. Stockholders of record on Tuesday, February 17th were issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 1.1%. The ex-dividend date of this dividend was Tuesday, February 17th. STERIS’s dividend payout ratio (DPR) is presently 35.15%.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on STE shares. Wall Street Zen raised STERIS from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 7th. Weiss Ratings restated a “buy (b)” rating on shares of STERIS in a report on Friday, January 9th. Six equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $275.20.

Get Our Latest Analysis on STE

STERIS Profile

(Free Report)

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.